In vivo regeneration of insulin-producing beta-cells

Adv Exp Med Biol. 2010:654:627-40. doi: 10.1007/978-90-481-3271-3_27.

Abstract

Type 1 and type 2 diabetes mellitus are considered to be caused by defective control of blood glucose resulting from a reduced beta-cell mass. Thus, the restoration of a functional beta-cell mass by replacing the damaged beta-cells or stimulating beta-cell regeneration is a logical approach for the treatment of diabetes. Strategies for increasing the beta-cell mass include stimulating beta-cell replication and differentiation and inhibiting beta-cell death. Treatment with various growth factors such as GLP-1, BTC, HGF, and EGF and forced expression of beta-cell transcription factors such as Pdx-1, NeuroD, and MafA resulted in the regeneration of beta-cells in vivo. Another approach is the administration of stem/progenitor cells, which can differentiate into insulin-producing cells. However, there are no satisfactory methods yet for clinical application. Understanding the mechanisms of the regenerative process of pancreatic beta-cells will pave the way for the development of regenerative medicine for treatment of diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Differentiation
  • Cell Proliferation
  • Glucagon-Like Peptide 1 / metabolism
  • Humans
  • Insulin / metabolism*
  • Insulin-Secreting Cells / cytology*
  • Models, Biological
  • Pancreas / metabolism
  • Regeneration
  • Stem Cells / cytology
  • Transcription Factors / metabolism

Substances

  • Insulin
  • Transcription Factors
  • Glucagon-Like Peptide 1